NIAID will host a virtual workshop entitled “Mucosal Vaccines for SARS-CoV-2: Scientific Gaps and Opportunities” on November 7-8 2022 from 10-4 EST. The workshop will explore the state of the [...]
US National Institute of Allergy and Infectious Diseases (NIAID) Notice of Special Interest (NOSI)—Advancing Research Needed To Develop a Universal Influenza Vaccine: the purpose of the funding [...]
Conventional influenza vaccines are designed to stimulate neutralizing antibodies against immunodominant but highly variable hemagglutinin antigens. Inherent limitations include suboptimal [...]
“As the number of people infected with the coronavirus (which causes the coronavirus disease 2019, or COVID-19) continues to rise, the full extent and severity of this outbreak still [...]
“An unwelcome visitor during the holiday season has returned: influenza. As of today, six children have already fallen victim to the disease. And, as the Centers for Disease Control and [...]
“JERUSALEM, April 22, 2019 /PRNewswire/ — BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), announced today that the Management Committee of the European Investment Bank (EIB) agreed to [...]
“The first clinical trial of an innovative universal influenza vaccine candidate is examining the vaccine’s safety and tolerability as well as its ability to induce an immune response in [...]
“Work to develop a universal flu vaccine using a microneedle patch will continue at Georgia State University’s Institute for Biomedical Sciences with a $3.86 million grant from the National [...]
“Sen. Edward J. Markey (D-MA) and Rep. Rosa DeLauro (D-CT) recently reintroduced a measure designed to bolster the financial support for a universal influenza vaccine protecting against [...]
“FluGen, Inc. today announced preliminary data from a human challenge trial with its investigational intranasal M2SR vaccine showing, for the first time, protection against a highly [...]
